Reverse genetics of negative-sense RNA viruses, which enables one to generate virus entirely from cloned cDNA, has progressed rapidly over the past decade. However, despite the relative ease with which nonsegmented negative-sense RNA viruses can now be produced from plasmids, the ability to generate viruses with segmented genomes has lagged considerably, largely because of the inherent technical difficulties in providing all viral RNAs and proteins from cloned cDNA. A breakthrough in reverse genetics technology in the influenza virus field came in 1999, when we (Neumann et al., 1999, Proc. Natl. Acad. Sci. USA 96, 9345-9350) and others (Fodor et al., 1999, J. Virol. 73, 9679-9682) exploited a new approach to viral RNA production. In this review, we discuss the background for this advance, the systems that are now available for the generation of influenza viruses, and the implications of these developments for the future of virus research.
Influenza virus belongs to the family Orthomyxoviridae and contains a segmented RNA genome of negative polarity. In contrast to most other negative-sense RNA viruses, influenza virus replicates in the nucleus of infected cells (reviewed in Lamb and Krug, 1996) . After receptor-mediated endocytosis and fusion of the viral and cellular membranes, the viral ribonucleoprotein (vRNP) complex is released into the cytoplasm. The vRNP complex, composed of the viral RNA (vRNA), nucleoprotein (NP), and three polymerase proteins (PB2, PB1, and PA), is transported to the nucleus where transcription and replication occur. The negative-sense vRNA (complementary to mRNA in its orientation) does not serve as a direct template for protein synthesis; rather, the vRNA encapsidated by NP must be transcribed into mRNA by the viral polymerase complex. During replication, the vRNA serves as a template for the synthesis of a full-length complementary RNA (cRNA), which in turn serves as a template for progeny vRNA synthesis. Thus, for influenza virus replication, the minimal functional unit is the vRNP complex. The generation of influenza A virus therefore requires eight functional RNP complexes that must be delivered into the cell nucleus.
Attempts to generate influenza virus in the laboratory began in the 1980s, when replication-competent vRNPs were isolated from detergent-disrupted viruses (Plotch et al., 1981) or infected cells (Beaton and Krug, 1986) . These early studies demonstrated that vRNP complexes are sufficient for the replication of influenza virus RNA, but synthetic viral RNAs must be assembled into functional vRNP complexes to artificially generate influenza virus. This goal was partially reached in the late 1980s, when Parvin et al. (1989) and later Honda et al. (1990) reported the reconstitution of functional RNP complexes in vitro. Purified polymerase and NP proteins formed functional complexes that transcribed a synthetic RNA template and, more importantly, full-length viral RNA purified from virions. With the new-found ability to generate functional vRNP complexes, researchers directed their attention to techniques for introducing these (modified) vRNPs into virions.
In 1989, Palese and colleagues established the first system for modifying negative-sense RNA viruses (see Luytjes et al., 1989) , ushering in a new era of recombinant virus research using viruses containing vRNA derived solely from cloned cDNA (Fig. 1) . Enami et al. (1990) assembled in vitro transcribed vRNA and purified NP and polymerase proteins into RNP complexes. Once these complexes were transfected into eukaryotic cells, helper virus infection provided the remaining vRNPs, resulting in a recombinant virus comprised of one of the vRNAs derived from cloned cDNA. However, in this system, the vast majority of progeny viruses are helper viruses, requiring strong selection systems based on antibody-mediated growth restriction (Barclay and Palese, 1995; Horimoto and Kawaoka, 1994; Rowley et al., 1999) , temperature sensitivity Li et al., 1995; Yasuda et al., 1994) , host-range restriction (Enami et al., 1990; Subbarao et al., 1993) , or drug resistance (Castrucci and Kawaoka, 1995) . Although selection systems were eventually established for six of the eight influenza A viral segments [PB2 (Subbarao et al., 1993) , HA , NP (Li et al., 1995) , NA (Enami et al., 1990) , M (Castrucci and Kawaoka, 1995) , and NS ], and for the HA and NA segments of influenza B virus (Barclay and Palese, 1995; Rowley et al., 1999) , their application was technically demanding and the power of selection quite limited. Consequently, efforts for modifying the influenza virus genome using this experimental tactic were continued in only a few laboratories.
New impetus was lent to the reverse genetics of influenza virus when Hobom and colleagues, using RNA polymerase I for the intracellular synthesis of influenza virus RNA (Fig. 1) , established an alternative system for the generation of influenza viral RNA (see Neumann et al., 1994) . RNA polymerase I is an abundant nuclear enzyme that transcribes ribosomal RNA (rRNA), whichlike influenza vRNA-does not contain 5Ј-cap or 3Ј-poly(A) structures. Moreover, RNA polymerase I initiates and terminates transcription at defined promoter and terminator sequences that do not extend into the transcribed region. Hence, RNA polymerase I transcription yields transcripts that do not contain additional nucleotides at their 5Ј or 3Ј ends. Neumann et al. (1994) cloned a virus-like cDNA under the control of RNA polymerase I promoter and terminator sequences. After transfection, this group found that cellular RNA polymerase I synthesized an influenza virus-like RNA. Pleschka et al. (1996) employed this system to generate recombinant influenza virus by producing NA vRNP in the nucleus and infecting cells with helper virus to provide the remaining vRNP complexes, although selection systems were still required to isolate recombinant virus from the background of helper virus. The RNA polymerase I system is more convenient than the RNP transfection method because it circumvents the need for in vitro transcription, protein purification, and in vitro RNP assembly. However, with both of these helper virus-dependent systems, the efficiencies of virus generation were very low, precluding the generation of viruses with severe growth defects.
In 1994, Conzelmann and colleagues (see Schnell et al., 1994) generated rabies virus (family Rhabdoviridae) from cloned cDNA for the first time for negative-stranded RNA viruses. A full-length cDNA construct encoding the antigenomic positive-sense cRNA was cloned under the control of the T7 RNA polymerase promoter and the hepatitis delta ribozyme. The resultant plasmid was transfected into eukaryotic cells that had been infected with recombinant vaccinia virus expressing T7 RNA polymerase. Cells were cotransfected with protein expression plasmids for the components of the viral transcription complex, all under control of the T7 RNA polymerase promoter. Similar approaches led to the production of all genera of the Rhabdoviridae and Paramyxoviridae families (Baron and Barret, 1997; Buchholz et al., 1999; Clarke et al., 2000; Collins et al., 1995; Durbin et al., 1997; Garcin et al., 1995; Gassen et al., 2000; He et al., 1997; Hoffman and Banerjee, 1997; Jin et al., 1998; Kato et al., 1996; Lawson et al., 1995; Peeters et al., 1999; Radecke et al., 1995; Romer-Oberdorfer et al., 1999; Whelan et al., 1995) . These successes were soon translated into advances with segmented negative-sense RNA viruses.
In 1996, Bridgen and Elliott, using the approach outlined by Conzelmann's group (see Schnell et al., 1994) , produced a recombinant Bunyamwera virus, family Bunyaviridae, whose genome is composed of three segments of negative-sense RNA. Systems were thus in place for generating both nonsegmented and segmented negative-sense RNA viruses. A conspicuous exception was influenza virus, whose generation involves the added complexity of synthesis of eight (rather than three) viral RNAs, in addition to the polymerase and nucleoprotein from cloned cDNA.
Technical obstacles to generating influenza virus entirely from cloned cDNA were overcome in 1999, when our research group cloned cDNAs encoding all eight segments of the A/WSN/33 (H1N1) virus between human RNA polymerase I promoter and mouse RNA polymerase I terminator sequences (Neumann et al., 1999) (Fig. 2) .
FIG. 1.
Helper virus-dependent systems for the production of influenza virus possessing a single gene derived from cloned cDNA. In the ribonucleoprotein (RNP) transfection method, purified polymerase and nucleoprotein (NP) are mixed with in vitro synthesized vRNA to assemble functional RNP complexes. Cells are then transfected with the RNP complexes and infected with influenza helper virus (to provide the remaining seven RNPs). In the RNA polymerase I system, cells are transfected with a plasmid containing a cDNA that encodes one of the viral RNAs, flanked by RNA polymerase I promoter (P) and terminator (T) sequences. Transcription by cellular RNA polymerase I yields influenza vRNA that is replicated, transcribed, and packaged into progeny virus particles after infection with influenza helper virus. Both systems require stringent selection systems to select recombinant virus from the background of helper virus. After transfection of the resultant constructs in eukaryotic 293T (human embryonic kidney) cells, transcription by cellular RNA polymerase I yielded all eight vRNAs. In the initial experiments, cells were also cotransfected with plasmids expressing all nine structural proteins. Despite the introduction of 17 plasmids into cells (8 for the synthesis of RNA segments and 9 for protein expression), this approach yielded more than 1 ϫ 10 7 infectious viruses per milliliter of supernatant from cells transfected with the plasmids. More recently, by improving the system's parameters, we have produced more than 1 ϫ 10 8 infectious particles per milliliter of the supernatant, even with use of only four proteins (PA, PB1, PB2, and NP) for viral RNA transcription and replication. Although 12 plasmids are still required in our RNA polymerase I system for influenza A virus generation, it remains one of the most efficient systems yet reported (Pekosz et al., 1999) . We attribute this to the high transfection efficiency of 293T cells, leading to a pool of cells that receive the full complement of constructs required to initiate virus replication. Further, RNA polymerase I is abundantly expressed in growing cells, thus ensuring efficient replication of RNA polymerase I constructs. In addition to its high level of efficiency, the RNA polymerase I system is quite simple, requiring only DNA cloning and transfection techniques, which are well established in most virology laboratories. Fodor et al. (1999) also reported the generation of influenza A virus using a similar system; a hepatitis delta virus ribozyme was used instead of the RNA polymerase I terminator to produce vRNA possessing the authentic 3Ј end sequence.
Most nonsegmented negative-sense RNA viruses have been generated from antigenomic, positive-sense cRNA (reviewed in Roberts and Rose, 1998) . Either cRNA or vRNA was used to produce hPIV3 (Durbin et al., 1997) and Sendai virus (Kato et al., 1996) ; however, the latter template was less efficient in viral generation. For influenza virus production, negative-sense vRNA was superior to cRNA as a template for influenza virus production ; our unpublished data), possibly because with the nuclear RNA polymerase I system, it is unlikely that negative-sense vRNAs hybridize with positive-sense mRNAs in the cytoplasm, which is believed to affect the efficiency of virus generation in the T7 RNA polymerase system. Furthermore, stretches of uridine residues followed by hairpin structures, found in the genomes of nonsegmented negative-sense RNA viruses, may mimic the T7 RNA polymerase terminator structure, causing premature termination of transcription. By contrast, constraints that apply to the T7 RNA polymerase system, such as unwanted hybridization events or premature termination, do not impinge on the efficiency of virus generation in the RNA polymerase I system.
A modification of the RNA polymerase I system, designated RNA polymerase I/II system, was reported by (Fig. 3) . Briefly, a cDNA encoding a viral segment was cloned in the negative-sense orientation between RNA polymerase I promoter and terminator sequences, and this cassette was in turn cloned in the positive-sense orientation between an RNA polymerase II promoter (CMV early promoter) and a polyadenylation sequence. Transcription by RNA polymerase I yields negative-sense vRNA, whereas transcription by RNA polymerase II results in positive-sense mRNA synthesis. Thus, both vRNA and mRNA are generated from the same template, circumventing the need for protein expression constructs. Consequently, virus can be generated from 8 instead of 12 plasmids, reducing the number of plasmids required for virus generation. Therefore, this system may be useful for cell lines that otherwise cannot be transfected with a high level of efficiency. In the RNA polymerase I/II system, both protein expression and vRNA synthesis are achieved from the same template. Therefore, this system does not allow generation of virus-like particles lacking or containing lethal mutations in one or more viral segments. These limitations notwithstanding, both systems provide excellent tools for experimental mutagenesis directed at understanding influenza virus biology.
The RNA polymerase I system described above allows one to introduce any desired mutation into the genome of influenza virus. This capability opens the way to address such long-standing biologic issues as the nature of viral regulatory sequences, structure-function relationships, pathogenicity, and host cell tropism. Of particular importance is the identification of factors determining viral pathogenicity.
Perhaps the most intriguing potential application of reverse genetics systems for influenza virus generation is the creation of live-attenuated virus vaccines. Current inactivated vaccines effectively reduce the severity of influenza-associated complications, but they do not prevent infection. A cold-adapted live-attenuated vaccine now in clinical trials (Maassab and Bryant, 1999) provides better protection than conventional inactivated vaccines in young children, but only comparable protection in adults (Boyce and Poland, 2000) . Moreover, it contains only a limited number of amino acid replacements (Cox et al., 1988; Herlocher et al., 1996) , suggesting a potential risk for emergence of a revertant virus upon use in a large population, even though the virus was phenotypically stable in clinical trials. Thus, there is room for improvement. The RNA polymerase I systems for virus generation are capable of producing a master strain of influenza virus with multiple attenuating mutations in the genes encoding internal proteins. In the near future, reverse genetics could be used to produce a high-yield reassortant virus that possesses the HA and NA from a currently circulating strain. Moreover, reverse genetics systems could be exploited in the production of inactivated vaccines, which currently are generated by conventional genetic reassortment procedures.
Influenza viruses may serve as potentially useful vectors for gene transfer into mammalian cells. Indeed, studies with helper virus-dependent reverse genetics systems have demonstrated that influenza virus can accommodate additional genetic material. For several short polypeptides, including the V3 loop of HIV-1 gp120 protein (Li et al., 1993a) , a highly conserved epitope from the ectodomain of HIV-1 gp41 (Muster et al., , 1995 , a CD8 ϩ T-cell epitope from the circumsporozoite protein of Plasmodium yoelli (Li et al., 1993b) , and a B-cell epitope from the outer membrane protein F of Pseudomonas aeruginosa (Gilleland et al., 1997) , insertion in the antigenic sites of HA resulted in immune responses against the foreign epitope. For the expression of foreign fulllength proteins, the gene of interest can be physically linked to one of the influenza virus genes. Protein expression can then be achieved by internal ribosomal entry sites (IRES) or the footand-mouth disease virus 2A protease . In these approaches, the foreign genetic material is transcribed or translated as part of an influenza viral gene. Alternatively, foreign proteins can be expressed from an additional gene segment. rescued an artificial segment encoding wild-type NS1, but no NS2 protein, in a helper virus containing a ts mutation in NS1. Thus, this virus requires nine gene segments for efficient replication at a nonpermissive temperature, demonstrating the viability of influenza viruses containing more than eight genomic segments. To maintain additional segments in the absence of any selective pressure, one could use mutant influenza virus promoters that result in overreplication and/or overtranscription of the target gene (Neumann and Hobom, 1995) , an approach explored by Zhou et al. (1998) for the generation of recombinant influenza virus expressing the E2 glycoprotein of classical swine fever virus.
Safe and efficient delivery of foreign genetic material into cells could be achieved by virus-like particles (VLPs), i.e., particles that do not contain the full complement of viral RNAs. The expression of all viral (structural) proteins and an influenza virus-like RNA encoding a reporter gene results in the efficient generation of VLPs (Mena et al., 1996; Gomez-Puertas et al., 1999; Neumann et al., 2000b) . The delivery of foreign genes could then be accomplished by transfection with protein expression constructs encoding all viral structural proteins and with RNA polymerase I constructs encoding the proteins required for replication and transcription (i.e., the polymerase and NP, together with the gene of interest). The resultant infectious particles could be used for a subsequent round of infection to deliver the foreign gene into target cells, where the polymerase and NP proteins would be expressed and drive replication and transcription of the target gene, resulting in its expression. Since the virus-like particles do not contain vRNAs encoding structural proteins, no progeny particles are generated after gene delivery, thus ensuring the safety of the delivery system. Furthermore, the availability of 15 HA and 9 NA subtypes would alleviate the risk of immunoresistance to vector-generated proteins, allowing the repeated administration of VLPs.
Reports are now beginning to emerge that illustrate the versatility of the new reverse genetics systems. Using the RNA polymerase I/II system, regenerated an A/Teal/HK/W312/97 (H6N1) virus (isolated from a dead teal during the influenza virus outbreak in Hong Kong in 1997). Furthermore, they generated reassortants between the A/WSN/33 (H1N1) and the A/Teal/HK/W312/97 (H6N1) viruses and found that the introduction of the A/WSN/33 HA or NA genes into the Teal/HK/W312/97 background resulted in a significant reduction in virus titers. Thus, the approach outlined in this study may help researchers to elucidate the factors that determine viral pathogenicity (see Hatta et al., in press) .
Two other studies used the RNA polymerase I system to determine the function of influenza virus proteins. Neumann et al. (2000a) generated virus-like particles that entirely lacked or possessed mutations in the NS2 gene and examined the effect of these modifications on vRNP nuclear export (Fig. 4) . This study confirmed, in the context of viral infection, a previous finding by O 'Neill et al. (1998) that NS2 is critical for vRNP nuclear export, mediated by a nuclear export signal in the N-terminal region of NS2. Insights into the role of the M2 ionchannel protein were provided by Watanabe et al. (2001) . Viruses were generated that lacked or contained mutations in the M2 transmembrane domain, indicating that influenza A viruses can undergo multiple cycles of replication without M2 ion-channel activity in cell culture.
However, viruses defective in M2 ion-channel activity did not efficiently replicate in mice, demonstrating that this activity is critical for the viral life cycle. Similar approaches could be employed to determine the functions of other influenza virus proteins or cellular events involving specific viral proteins.
RNA polymerase I-based systems for the generation of influenza A virus provide, for the first time, powerful tools for the modification of the influenza virus genome with only minimal technical difficulties. With wider application of this procedure, we can look forward to accelerated progress in understanding the influenza virus life cycle, the generation of live-attenuated vaccines, and the use of influenza A virus as vaccine and gene delivery vectors. Moreover, the RNA polymerase I system may prove useful in the "de novo" synthesis of other viruses in the Orthomyxoviridae family, including influenza B and C viruses and Thogotovirus, as well as segmented negative-sense RNA viruses of the Bunyaviridae or Arenaviridae families, which replicate in the cytoplasm of infected cells. Flick and Pettersson (2001) demonstrated the nuclear export of RNA polymerase I transcripts during synthesis of an Uukuniemi virus-like transcript (family Bunyaviridae). Thus, the RNA polymerase I system may provide an alternative method for generating nonsegmented negative-sense RNA viruses and could possibly result in more efficient production of these viruses than could be achieved with the conventional T7 RNA polymerase system.
